Compass Pathways (CMPS): A Commercial Story Is Quietly Taking Shape

A Glimpse Into Infrastructure-like Unit Economics

This will be a “best ideas only” bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

*Update to my PT below*

I’ve written about Compass before, largely through the lens of clinical risk and regulatory uncertainty. Since then, two things have changed in a meaningful way:
(1) the company’s posture has shifted from “prove the science” to “prepare the system,” and
(2) the regulatory environment around psychedelic therapies (while still restrictive on paper) has begun to formalize in practice.